Genmab A (GMAB) Non-Current Assets (2018 - 2026)
Genmab A (GMAB) posted Non-Current Assets of $9.8 billion for Q1 2026, down 1.85% on a QoQ basis from $10.0 billion in Q4 2025, and up 284.58% year-over-year from $2.5 billion in Q1 2025.
Genmab A (GMAB) Non-Current Assets (2018 - 2026) Analysis & Trends
Genmab A's Non-Current Assets history runs 7 years deep, the most recent figure standing at $9.8 billion for Q1 2026.
- Quarterly Non-Current Assets rose 284.58% year-over-year to $9.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 billion (up 75.02% YoY) and the FY2025 annual result came in at $10.0 billion, up 297.3% from the prior year.
- Non-Current Assets was $9.8 billion for Q1 2026 at Genmab A, down from $10.0 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.0 billion in Q4 2025 and bottomed at $320.0 million in Q4 2023.
- A 4-year average of $3.7 billion and a median of $2.5 billion in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets jumped 685.62% — and 2025, when it climbed 6.38%.
- Genmab A's Non-Current Assets stood at $320.0 million in 2023, then soared by 685.62% to $2.5 billion in 2024, then soared by 297.3% to $10.0 billion in 2025, then decreased by 1.85% to $9.8 billion in 2026.
- Business Quant data shows GMAB's Non-Current Assets at $9.8 billion in Q1 2026, $10.0 billion in Q4 2025, and $2.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | 9.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.80 Bn |
| Dec 31, 2025 | 9.99 Bn |
| Sep 30, 2025 | 2.55 Bn |
| Jun 30, 2025 | 2.55 Bn |
| Mar 31, 2025 | 2.55 Bn |
| Dec 31, 2024 | 2.51 Bn |
| Sep 30, 2024 | 2.40 Bn |
| Mar 31, 2024 | 335.00 Mn |
| Dec 31, 2023 | 320.00 Mn |
| Sep 30, 2020 | 2,018.00 |
| Dec 31, 2019 | 1,074.00 |
| Sep 30, 2019 | 1.07 Bn |
| Dec 31, 2018 | 831.75 Mn |